Newsletter: aHUS Global Advocate, 9th Edition
The aHUS Global Advocate Newsletter, highlights of news & views with a focus on the rare disease atypical HUS. Our 9th Edition, March 2024
The aHUS Global Advocate Newsletter, highlights of news & views with a focus on the rare disease atypical HUS. Our 9th Edition, March 2024
Today is World Kidney Day. An annual awareness day to bring kidney disease matters to the world’s attention. aHUS is a…
The Steven Spielberg of aHUS videos (Jeff) has produce another aHUS video for RDD24. Sixty six aHUS patients /carers starred in…
Those new to the disease aHUS may not know the significant contribution that Dr Leonard Bell has made to their treatment…
aHUS epidemiology is the about how many aHUS patients there are. The numbers onsetting and surviving. It’s “Incidence” and “prevalence”. How…
In September last year a group of aHUS patients and parent/carers met with FDA and told them about aHUS. A summary…
FDA has approved the use of Iptacopan, brand name Fabhalta, for PNH. Two trials demonstrated that this Factor B complement inhibitor…
Affordable treatment is a big issue for the majority of the world’s aHUS patients. Many live in countries that cannot afford…
To the best of Global Action’s knowledge there has not been a trial of subcutaneous Ravulizumab for use in the treatment…